Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Jorge, Milone"'
Autor:
Cecilia Alejandra Lang, Juan Maradei, Martín Beccacece, Andrés Furque, Tania Encina, Pablo Pombo, Guillermina Remaggi, Paola Ochoa, Lisa Lopez Ares, Magalí Colucci, Natali De Paul, Florencia Rios Sant, Mercedes Vazquez, Priscilla Lemuñir, Santiago Boughen, Martín Brandt, Romina Calmet, Celia Castello, Roberto Ferreras, Paola Giarini, Laura Jones, Nazarena Martin, Diego Moro, Julieta Pasquali, María del Carmen Rios Part, Ruben Di Chiara, Gustavo Taborda, Rosana Venchi, Marisa Sandoval, Paula Iommi, Federico Torreguitart, Evangelina Agriello, Jorge Milone
Publikováno v:
Revista Hematología. 26:28-35
Las alteraciones citogenéticas (AC) constituyen uno de los factores pronósticos más importantes en los pacientes con mieloma múltiple (MM) permitiendo dividirlos en dos grupos de riesgo (estándar y alto) con diferente pronóstico y enfoque terap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ea1ebed20038362de5a95d07b7988cb
https://doi.org/10.48057/hematologa.v26i2.442
https://doi.org/10.48057/hematologa.v26i2.442
Autor:
Sergio Orlando, Paola Ochoa, Cecilia Foncuberta, Patricio Duarte, Soledad Zabaljauregui, Florencia Aizpurua, Sergio Lopresti, Dorotea Fantl, Gonzalo Garate, Jorge Milone, Dardo Riveros, Natalia Schutz, Claudia Shanley, Sebastian Yantorno, Elvira Giannini
Publikováno v:
Expert Review of Hematology. 14:315-322
We compared the efficacy of lenalidomide-dexamethasone (Rd) based treatments for relapsed/refractory multiple myeloma patients (pts), in a real-world setting. In addition, we evaluated adverse even...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8aef38a115cee61cba84333b1e76d6bd
https://doi.org/10.1080/17474086.2021.1886073
https://doi.org/10.1080/17474086.2021.1886073
Autor:
Monica Bellei, Carlos Sergio Chiattone, Stefano Luminari, Emanuela Anna Pesce, Maria Elena Cabrera, Carmino Antonio de Souza, Raul Gabús, Lucia Zoppegno, Jorge Milone, Astrid Pavlovsky, Joseph Michael Connors, Francine Mary Foss, Steven Michael Horwitz, Raymond Liang, Silvia Montoto, Stefano Aldo Pileri, Aaron Polliack, Julie Marie Vose, Pier Luigi Zinzani, Emanuele Zucca, Massimo Federico
Publikováno v:
Revista Brasileira de Hematologia e Hemoterapia, Vol 34, Iss 1, Pp 42-47 (2012)
Peripheral T-cell lymphomas are a group of rare neoplasms originating from clonal proliferation of mature post-thymic lymphocytes with different entities having specific biological characteristics and clinical features. As natural killer cells are cl
Externí odkaz:
https://doaj.org/article/b2663c39d43743a5825f50e421d3aa63
Autor:
Patricio Jose, Duarte, Natalia Paola, Schutz, Paola, Ochoa, Sebastian, Yantorno, Sergio, Orlando, Sergio, Lopresti, Soledad, Zabaljauregui, Florencia, Aizpurua, Claudia, Shanley, Elvira, Giannini, Gonzalo, Garate, Cecilia, Foncuberta, Jorge, Milone, Dardo, Riveros, Dorotea, Fantl
Publikováno v:
Expert review of hematology. 14(3)
We compared the efficacy of lenalidomide-dexamethasone (Rd) based treatments for relapsed/refractory multiple myeloma patients (pts), in a real-world setting. In addition, we evaluated adverse events (AE), progression-free survival (PFS) and overall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::49d35a0710b610f06360042c9c6d24a5
https://pubmed.ncbi.nlm.nih.gov/33541156
https://pubmed.ncbi.nlm.nih.gov/33541156
Autor:
José I. Trucco, Mariano Berro, Ana Lisa Basquiera, Pablo García, Sebastián Yantorno, Silvina Palmer, Alejandro Requejo, Adriana Vitriú, Gonzalo Bentolila, María Marta Rivas, Gonzalo Ferini, Juan José García, Jorge Milone, German Stemmelin, Gregorio Jaimovich, Cecilia Foncuberta, Juliana Martínez Rolón, Gustavo D. Kusminsky
Publikováno v:
Medicina (Buenos Aires), Vol 80, Iss 6, Pp 654-662 (2020)
We retrospectively analyzed 570 adult patients who received allogeneic stem cell transplantation for malignant diseases. The outcomes were compared according to donor type. Most of the patients (60%) were transplanted for acute leukemia. Median follo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c2c62208b34d09e28fb78e00c8559faf
https://pubmed.ncbi.nlm.nih.gov/33254110
https://pubmed.ncbi.nlm.nih.gov/33254110
Autor:
Luciana C Ferrari, María M Rivas, Isolda I Fernandez, Federico Sackmann, María J Mela Osorio, Alicia B Navickas, Lucía Agamennoni, Irene Rey, Laura Aguerre, Hernan Dick, Natalia Carnelutto, Mariela Gómez, María B Castro, Ana L Basquiera, Eliana Moya, Florencia Negri Aranguren, Pedro Negri Aranguren, Laura Fishman, Lucila Costa, Nicolás Cazap, Florencia Fornillo, María I Paganini, María L Rapan, Julian Freue, Manuela Clavijo, Roxana Ramírez, Jorge Milone, Miguel A Pavlovsky, Carolina B Belli, María M Moirano, On behalf of Acute Leukemia Committee Argentine Society of Hematology
Publikováno v:
Blood. 138:4471-4471
Background: ALL in adults is considered a heterogeneous disease with poor prognosis. However, adolescents and young adults (AYA) display intermediate characteristics as compared with children. Risk groups and response predictors are essential to guid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::794e02dcc9f471cd675726a450788618
https://doi.org/10.1182/blood-2021-151448
https://doi.org/10.1182/blood-2021-151448
Autor:
Catherine Thieblemont, Tetiana Skrypets, Young Hyeh Ko, Sabela Bobillo Varela, Giorgio Inghirami, Monica Civallero, Won Seog Kim, Dennis D. Weisenburger, Massimo Federico, Jorge Milone, Mario Bargetzi, Carmino Antonio De Souza, Stefano Pileri, Raul Gabus, Kenneth R. Carson, Martina Manni, Steven M. Horwitz, Silvia Montoto, Astrid Pavlovsky, Ranjana H. Advani, Julie M. Vose
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S253-S254
Background: Angioimmunoblastic T-cell lymphoma (AITL) is a rare and unique subtype of peripheral T-cell lymphoma (PTCL) with distinct clinicopathologic features. Clinical presentation is varied with an aggressive course and dismal outcomes. Curative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5259ad1931c43ccc04688a9fe2bd9c61
https://doi.org/10.1016/s2152-2650(20)30851-x
https://doi.org/10.1016/s2152-2650(20)30851-x
Autor:
Jorge Milone, Philippe Rousselot, Andreas Hochhaus, Giuseppe Saglio, Diane Healey, Charles A. Schiffer, Delphine Rea, Hesham Mohamed, Hagop M. Kantarjian, Jorge E. Cortes, Neil P. Shah
Publikováno v:
American Journal of Hematology. 91:869-874
Dasatinib was approved at 100 mg once daily for imatinib-resistant or -intolerant patients with chronic myeloid leukemia (CML) in chronic phase, based on results of the phase 3 CA180-034 (NCT00123474) study. Here we present the final 7-year analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a48a776db8a43d3f809821c452a3d8a7
https://doi.org/10.1002/ajh.24423
https://doi.org/10.1002/ajh.24423
Autor:
Juan Julio Kassack Ipiña, Mohan B. Agarwal, Michele Baccarani, Tadeusz Robak, M. Brigid Bradley-Garelik, Maria Soledad Undurraga, Jianxiang Wang, Neil P. Shah, Christian Junghanss, Franck E. Nicolini, Jorge Milone, Michinori Ogura, Andreas Hochhaus, Edo Vellenga, Dong-Wook Kim, Hagop M. Kantarjian, Jorge E. Cortes, Carolina Pavlovsky, Chao Zhu, Jan Van Droogenbroeck
Publikováno v:
Blood, 119(5), 1123-1129. AMER SOC HEMATOLOGY
Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 DASISION trial, patients with newly diagnosed chronic-phase (CP) CML we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06f8b2d672a35a69619d91fd8a828240
https://research.rug.nl/en/publications/9c67a021-0682-44dd-a2ed-49e6fc203ed0
https://research.rug.nl/en/publications/9c67a021-0682-44dd-a2ed-49e6fc203ed0
Autor:
Hector Murro, Miguel de Tezanos Pinto, Maria Elisa Riva, Veronica Ventriglia, Beatriz Moiraghi, Jorge Milone, Emilio Lanari, Raquel Bengió, Michele Bianchini, Eduardo Bullorsky, Irene Larripa
Publikováno v:
Leukemia & Lymphoma. 52:1720-1726
In imatinib-treated patients with chronic myeloid leukemia (CML), BCR-ABL mutations are the most common mechanism of resistance. Here we report the first multicenter Argentinean study investigating mutations in those patients with CML who fail or los
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c3a38263711865ca22678c038ab5525
https://doi.org/10.3109/10428194.2011.578310
https://doi.org/10.3109/10428194.2011.578310